Sublingual Bupraxon Tablets in Cancer Patients: Initial Results from Real-World Clinical Practice
Open Access
- 21 April 2026
- journal article
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in New St. Petersburg Medical Records
- No. 4,p. 68-76
Abstract
Introduction. Adequate pain management in cancer patients remains a serious challenge. Long-term and uncontrolled use of NSAIDs is associated with a high risk of complications, while the use of opioids is often limited by their adverse effects, particularly constipation, and the potential risk of diversion. Combination drugs such as Bupraxon (buprenorphine + naloxone) represent a promising alternative.Objective. To present to the medical community the initial clinical experience with the domestic combined drug Bupraxon for sublingual administration in cancer patients with chronic pain syndrome (CPS).Methods and materials. This paper presents the results of a post-marketing observational study involving 22 cancer patients with CPS, as well as two detailed clinical case reports. The analgesic efficacy, time to onset and duration of action, tolerability, and safety of the drug were assessed in a real-world clinical setting.Results. Bupraxon was shown to provide effective control of moderate to severe intensity pain. The onset of action was observed within 30–45 minutes, and the duration of analgesia was 4–8 hours. For 12 out of 22 patients, an effective dose was titrated within 2–3 days. The drug was well-tolerated, with no significant gastrointestinal adverse events (specifically, no constipation) and no withdrawal syndrome following short-term use. The combination with naloxone enhances narcological safety by reducing the risk of abuse.Conclusions. Bupraxon is an effective and safe option for the management of CPS in cancer patients, particularly in those at risk of bowel obstruction. Its non-invasive form, controllable analgesia, and favorable safety profile make it a promising alternative to other opioid analgesics. Further comparative studies are required for a comprehensive assessment of the drug's potential.Keywords
This publication has 17 references indexed in Scilit:
- Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-AnalysisJournal of Pain and Symptom Management, 2016
- Determination of Buprenorphine and Naloxone in Patient Blood Plasma Using HPLC-MSPharmaceutical Chemistry Journal, 2015
- Outcome after Injections of Crushed Tablets in Intravenous Drug Abusers in the Helsinki University Central HospitalEuropean Journal of Vascular and Endovascular Surgery, 2009
- Trends in Abuse of OxyContin® and Other Opioid Analgesics in the United States: 2002-2004The Journal of Pain, 2005
- Pharmacokinetics of the combination tablet of buprenorphine and naloxoneDrug and Alcohol Dependence, 2003
- Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in FranceDrug and Alcohol Dependence, 2003
- Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphineDrug and Alcohol Dependence, 2000
- Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant ratsPsychopharmacology, 1989
- Buprenorphine: differential interaction with opiate receptor subtypes in vivo.The Journal of Pharmacology and Experimental Therapeutics, 1982
- Human Pharmacology and Abuse Potential of the Analgesic BuprenorphineArchives of General Psychiatry, 1978